Form D · Other

Awakn Life Sciences Corp.

Toronto, A6 · CIK 0001948724

Offering snapshot reported Jun 26, 2023 · SEC filing

Reported sold
$575K
Offering amount: $1.16M
Investors reported
5
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jun 14, 2023
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jun 26, 2023Initial$575,000No comparison5SEC filing
May 3, 2023Initial$575,000No comparison2SEC filing
Nov 21, 2022Initial$1,366,214No comparison9SEC filing
Sep 28, 2022Initial$130,152No comparison4SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired, Other
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-485100
Each unit consists of 1 cm sh & 0.75 cm sh purchase wrt. Each whole wrt entitles the holder to purchase 1 cm sh at a price of CDN0.63 for a period of 5 years following the closing date.

Source: Form D, filed Jun 26, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Paul Carter Director
James Collins Executive
Jonathan Held Executive
Shaun Mc Nulty Executive
Steve Page Director
John Papastergiou Director
George Scorsis Director
Benjamin Sessa Executive
Anthony Tennyson Director, Executive

Issuer details

Industry: Other (See others in industry)

Address:
301 217 Queen St West
Toronto, A6, M5V 0R2